A Study of JNJ-77474462 (Bermekimab) in Healthy Chinese Participants
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05252520
- Locations
- π¨π³
Nanfang Hospital of Southern Medical Hospital, Guangzhou, China
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
- Conditions
- Amyloidosis
- Interventions
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 150
- Registration Number
- NCT05250973
- Locations
- π¨π³
West China Hospital Si Chuan University, Chengdu, China
πΊπΈCity of Hope, Duarte, California, United States
πΊπΈSmilow Cancer Hospital/Yale Cancer Center, New Haven, Connecticut, United States
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Colitis, Ulcerative
- Interventions
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 577
- Registration Number
- NCT05242484
- Locations
- π«π·
CHU Saint Etienne, Saint Etienne, France
π«π·Hopital de Rangueil, Toulouse cedex 09, France
π«π·CHRU Nancy Brabois, Vandoeuvre les Nancy, France
A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 11
- Registration Number
- NCT05242445
- Locations
- π§πͺ
SGS Belgium NV, Edegem, Belgium
πͺπΈHosp. Gral. Univ. Valencia, Valencia, Spain
π΅π±PUNKT ZDROWIA Hlebowicz Jakubowski Lekarze sp.p., Gdansk, Poland
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
- Conditions
- Crohn's Disease
- Interventions
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 703
- Registration Number
- NCT05242471
- Locations
- ππ·
University Hospital Center Split, Split, Croatia
ππ·University Hospital Dubrava, Zagreb, Croatia
π¨πΏVojenska nemocnice Brno, Brno, Czechia
A Study of Ustekinumab Treatment in Children With Crohn's Disease
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 545
- Registration Number
- NCT05242458
- Locations
- πΊπΈ
ImproveCareNow, Inc., Burlington, Vermont, United States
A Study of JNJ-42847922 (Seltorexant) in Healthy Participants
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT05236868
- Locations
- π³π±
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands
A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 255
- Registration Number
- NCT05223868
- Locations
- π©πͺ
ISA - Interdisciplinary Study Association GmbH, Berlin, Germany
π©πͺNiesmann & Othlinghaus GbR, Bochum, Germany
π©πͺRosenpark Research GmbH, Darmstadt, Germany
Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
- Conditions
- Warm Autoimmune Hemolytic Anemia
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05221619
A Study of JNJ-64281802 in Healthy Adult Participants
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 33
- Registration Number
- NCT05201937
- Locations
- π³π±
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands